Drugs / Beta-Sitosterol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07457333 | Feb 2026 → Dec 2028 expected | acquired aneurysmal subarachnoid hemorrhage | Second Affiliated Hospital, School of Medicine, Zhejiang University | Enrolling by invitation | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT07547462 Comparator | Dec 2023 → Oct 2024 | endometriosis in cutaneous scar | Hamad Medical Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beta-Sitosterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07547462 ↗ |
| Known as | β-Sitosterol | “β-Sitosterol, a plant sterol with proven anti-inflammatory, antioxidant, and endothelial-protective effects.” NCT07457333 ↗ |
| Route | Oral | “administered orally” NCT07457333 ↗ |